<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ping An Biomedical Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd</link>
<description>Latest news and press releases for Ping An Biomedical Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 09 Jan 2026 14:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ping-an-biomedical-co-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-announces-142500739</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-announces-142500739</guid>
<pubDate>Fri, 09 Jan 2026 14:25:00 GMT</pubDate>
<description>HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”). The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 milli</description>
</item>
<item>
<title>Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-receives-120500982</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-receives-120500982</guid>
<pubDate>Fri, 09 Jan 2026 12:05:00 GMT</pubDate>
<description>HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors. Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magclou</description>
</item>
<item>
<title>Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-announces-110000546</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/ping-biomedical-co-ltd-announces-110000546</guid>
<pubDate>Fri, 28 Nov 2025 11:00:00 GMT</pubDate>
<description>Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the</description>
</item>
<item>
<title>Majestic Ideal Holdings Ltd Announces Approval of Name Change to "Ping An Biomedical Co., Ltd." at Extraordinary General Meeting</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-ltd-announces-approval-of-name-change-to-ping-an-biomedical-co-ltd-at-extraordinary-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-ltd-announces-approval-of-name-change-to-ping-an-biomedical-co-ltd-at-extraordinary-general-meeting</guid>
<pubDate>Fri, 12 Sep 2025 04:00:00 GMT</pubDate>
<description>HONG KONG, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Ltd (NASDAQ: MJID) (the “Company”) announced that during the Extraordinary General</description>
</item>
<item>
<title>Majestic Ideal Holdings Limited Announced Closing of Initial Public Offering</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-limited-announced-closing-of-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-limited-announced-closing-of-initial-public-offering</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Limited (Nasdaq: MJID) (the “Company”), a provider of SCM services in the apparel industry</description>
</item>
<item>
<title>Majestic Ideal Holdings Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq</title>
<link>https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-limited-announces-pricing-of-initial-public-offering-and-listing-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/ping-an-biomedical-co-ltd/news/majestic-ideal-holdings-limited-announces-pricing-of-initial-public-offering-and-listing-on-nasdaq</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Majestic Ideal Holdings Limited (Nasdaq: MJID) (the “Company”), a provider of SCM services in the apparel industry</description>
</item>
</channel>
</rss>